Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT07127822
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
A Randomized, Controlled, Non Inferiority Phase II Clinical Study Comparing Iparomlimab and Tuvonralimab With Standard Chemotherapy Combined With PD-1/PD-L1 Monoclonal Antibody as First-line Treatment for MSI-H/dMMR Recurrent/Metastatic Gastric Cancer
Sponsor: Peking University
Updated 1 time since 2025 Last updated: Aug 15, 2025 Started: Sep 1, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07127822, this PHASE2 trial focuses on Gastric / Gastroesophageal Junction Adenocarcinoma and MSI-H Cancer and remains actively recruiting participants. Sponsored by Peking University, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peking University
- Peking University Cancer Hospital & Institute
- Qilu Pharmaceutical Group Co., Ltd
Data source: Peking University
For direct contact, visit the study record on ClinicalTrials.gov .